Key takeaways
Glyxambi (empagliflozin / linagliptin) and Januvia (sitagliptin) are both medications used to treat Type 2 diabetes. They help manage blood sugar levels, but they belong to different medication classes. Glyxambi is a combination of an SGLT2 inhibitor (empagliflozin) and a DPP-4 inhibitor (linagliptin), while Januvia is solely a DPP-4 inhibitor. Glyxambi is taken once daily in the morning and can also lower the risk of death from heart problems in adults with Type 2 diabetes and heart disease. Januvia is also taken once daily but does not have this additional heart benefit. Glyxambi may cause side effects like urinary tract infections and upper respiratory tract infections, while Januvia can cause a runny or stuffy nose and headaches. Both medications can cause serious side effects like pancreatitis and severe skin reactions, but Glyxambi also has a risk of ketoacidosis and dehydration. Neither medication is available in a generic form.
